rosiglitazone + peginterferon alfa-2a + ribavirin

This is a potential combination therapy consisting of rosiglitazone, peginterferon alfa-2a, and ribavirin. Based on the provided search results, information specifically regarding this *triple* combination for therapeutic use, particularly for hepatitis C virus (HCV) infection, is not available. The search results primarily discuss the *double* combination of peginterferon alfa-2a and ribavirin, which is a well-established treatment for chronic HCV infection. Peginterferon alfa-2a is a modified interferon that, when combined with ribavirin, has shown significantly higher sustained virologic response rates for HCV compared to older regimens. Rosiglitazone is typically used as an antidiabetic medication (a thiazolidinedione) to improve insulin sensitivity; its role in combination with peginterferon and ribavirin for HCV or any other indication is not described in the provided information.